Ipamorelin

Multi-Buy Savings — Add 2+ products to save 10% automatically. Add 3+ to save 15%. Applied at checkout.

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide and the first truly selective growth hormone secretagogue (GHS), developed as a tool to distinguish GHRP-mediated GH release from off-target ACTH, cortisol, and prolactin stimulation seen with earlier GHRPs such as GHRP-2 and GHRP-6. It acts as a potent, selective agonist at the ghrelin receptor (GHS-R1a).

Ipamorelin's exceptional GH-specificity makes it particularly valuable in research on the ghrelin/GHS-R1a axis, pituitary somatotroph function, and GH/IGF-1 pathway modulation without the confounding endocrine effects of less selective GHRPs. Pharmacokinetic studies in humans have characterised its dose-proportional GH stimulation profile, short half-life (~2 h), and clean endocrine selectivity profile.

CAS: 170851-70-4  ·  Formula: C38H49N9O5  ·  MW: 711.9 g/mol  ·  Purity: ≥99% HPLC  ·  Format: Lyophilised powder  ·  Storage: −20 °C

Research Areas: GHS-R1a / ghrelin receptor pharmacology · Selective GH secretagogue · Pituitary somatotroph biology · GH/IGF-1 pathway · Endocrine selectivity studies · Metabolic research

Selected Research Literature:
• Ipamorelin: the first selective growth hormone secretagogue (PMID 9849822)
• PK/PD modelling of ipamorelin in human volunteers (PMID 10496658)
• Ipamorelin as a novel ghrelin mimetic (PMID 19289567)

Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.